What is the prognosis of ulcerative colitis?

作者
Kevin P. Rioux
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
卷期号:14 (Supplement): S52-S53 被引量:6
标识
DOI:10.1097/00054725-200810001-00027
摘要

A patient with newly diagnosed ulcerative colitis (UC) will typically be aged 15–35 years and will already have suffered many of the troubling, embarrassing, and debilitating symptoms that characterize this chronic illness. They will want to know in succinct terms what to reasonably expect in the months and years ahead. This article provides a brief synopsis of the presentation, course, and long-term outcomes of UC. There are 4 general patterns that describe the clinical presentation and evolution of ulcerative colitis.1 1) In up to 90% of patients, UC follows the typical relapsing and remitting course. 2) Assuming the diagnosis of UC is correct, some patients may experience only 1 attack of the disease followed by long-term remission (18% at 5 years and 10% at 25 years). 3) Approximately 10% of patients with UC present with fulminant or intractable severe disease and, as such, will undergo panproctocolectomy on an urgent basis or within a year of diagnosis. 4) Finally, a very small percentage of patients (about 1% at 5 years and 0.1% at 25 years) will suffer from unremitting illness. The key predictors of the long- and short-term course of UC are: 1) longitudinal extent of colonic inflammation, and 2) clinical severity at presentation.2 Disease limited to the rectum represents about 40% of newly diagnosed patients, and 30%–40% of patients present with colitis confined to the left hemicolon. Total colonic involvement occurs in 20%–30% of patients and portends a poorer overall prognosis in terms of need for surgery3 and colon cancer risk.4 Severity is judged by a composite of clinical symptoms (e.g., frequency of bowel movements, hematochezia, fever, tachycardia) and laboratory parameters (e.g., C-reactive protein and hemoglobin) and by such indices about 80%–90% of patients at presentation will have mild–moderate disease.2 Reflecting severity and extent of disease, the required use of corticosteroid therapy at presentation is a marker of relatively poor prognosis. In a population-based cohort, only one-third of UC patients required steroid treatment at time of initial diagnosis, but half of these patients then required prolonged corticosteroid use or surgery.5 It is well described that UC tends to take a more aggressive course in nonsmokers or those who quit smoking. In addition to being protective against the development of UC, prior appendectomy in patients with UC tends to predict a milder course of the disease.6 There is some evidence that the severity of UC in an individual diminishes over time. Numerous serological and genetic markers have been identified in inflammatory bowel disease (IBD). There is promise that combinations of such markers may help define disease subsets and thus provide specific prognostic information to guide therapy.7 At present, however, testing for immunogenetic markers of IBD is not routinely available and there are not enough data to demonstrate a significant advantage over traditional clinical parameters in predicting the course of the disease. Proximal extension of UC does occur, usually early in the course of illness, and its likelihood relates to the initial extent of disease.3 Approximately 5% of those with proctitis and 20% of those with left-sided disease at the time of diagnosis will have more extensive involvement in 5 years. However, when observed for longer periods extension may occur in up to 45% and 70% of those initially diagnosed with proctitis and left-sided disease, respectively. The rate of panproctocolectomy for UC is ≈10% in the first year of illness, about 4% in the second year, and 1%/year thereafter.1,8 If colectomy is not required in the first 5 years of disease the likelihood of subsequently requiring colectomy for active disease is very low. Among those with pancolitis, the cumulative risk for colectomy is about 35% after 5 years, but even for those with only proctitis the rate of colectomy is still quite substantial, about 9%.1 More recent studies suggest that colectomy rates in UC are less than previously reported.9 The use of cyclosporine A (CsA) in hospitalized patients with refractory or fulminant colitis was shown to spare a significant number of patients from colectomy in the short term, but in longer follow-up at least half of patients require colectomy anyway.10 In many centers infliximab is replacing CsA as a surgery-sparing treatment in UC but enough data are not yet available on long-term outcomes.11 There appears to be an increase in mortality in the first few years after a diagnosis of UC, reflecting those with severe or fulminant disease and complications related to colectomy. Although the long-term survival of UC patients does not significantly differ from that of the general population, there is, however, excess mortality attributable to hepatobiliary disease and colorectal cancer (CRC).4 The risk of CRC begins to rise at 8–10 years after diagnosis of UC and, thus, it is recommended that endoscopic surveillance for dysplasia begin around this time. Due to biases and methodological limitations, early studies tended to significantly overestimate the risk of CRC in UC. Recent estimates show that the risk of CRC in UC is about 2% after 10 years, 8% after 20 years, and 18% after 30 years.12 Thus, the risk of CRC is 2–3× greater in patients with UC than the general population.13 CRC risk is greatest among those diagnosed at an early age (<15 years) and those with pancolitis.4 Coexisting primary sclerosing cholangitis and family history of colon cancer confer added risk of CRC in patients with UC. Quality of life (QOL) for patients with UC is impaired during periods of active disease and, even during remission, about one-third of patients continue to have impaired QOL due to physical symptoms consistent with irritable bowel syndrome. Disease-specific concerns include loss of bowel control, lack of energy, medication side effects, eminent flare of disease, and fear of colectomy or colorectal cancer, all of which significantly impact social and psychological functioning. To be sure, UC patients generally adapt well to their illness, and over 90% of UC patients feel that they have a normal physical activity level for their age and remain fully capable of employment.14 Individual patients with UC will have a highly variable experience and interpretation of their disease and, for the purposes of engaging trust and a facilitating a long-term therapeutic relationship, physicians should endeavor to ask about and understand the impact of UC on their patients' family, social, and professional lives.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chen发布了新的文献求助10
刚刚
曾曾曾曾完成签到 ,获得积分10
1秒前
shan发布了新的文献求助10
1秒前
苏黎世完成签到,获得积分10
1秒前
Yuan88发布了新的文献求助30
1秒前
2秒前
爆米花的应助被小胆采纳,获得10
2秒前
施夷光发布了新的文献求助50
2秒前
3秒前
哆啦A梦完成签到 ,获得积分10
3秒前
4秒前
Deannn778发布了新的文献求助10
4秒前
5秒前
郭泓嵩完成签到,获得积分10
5秒前
47发布了新的文献求助10
5秒前
酷波er的应助被blue0412采纳,获得10
7秒前
7秒前
Xcc发布了新的文献求助10
7秒前
酷波er的应助被sfjlyz采纳,获得10
7秒前
8秒前
Yuan88发布了新的文献求助30
8秒前
8秒前
8秒前
陌茉完成签到 ,获得积分10
9秒前
Luna666发布了新的文献求助30
9秒前
隐无名发布了新的文献求助10
10秒前
今后的应助被Lin采纳,获得10
10秒前
华仔的应助被月光疾风采纳,获得10
10秒前
初景发布了新的文献求助10
10秒前
JLW发布了新的文献求助10
11秒前
11秒前
12秒前
Yuan88发布了新的文献求助30
12秒前
13秒前
Owen的应助被Leolr10采纳,获得10
13秒前
北海qy完成签到,获得积分10
13秒前
14秒前
CipherSage的应助被Deannn778采纳,获得10
15秒前
yy发布了新的文献求助10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211